The Significance of VCAM-1, AOPP, HbA1c and FBG in Metformin Treatment of Diabetic Nephropathy

doi:10.11748/bjmy.issn.1006-1703.2018.01.013

PDF(2918 KB)

Labeled Immunoassays and Clinical Medicine ›› 2018, Vol. 25 ›› Issue (1) : 50-53. DOI: 10.11748/bjmy.issn.1006-1703.2018.01.013

The Significance of VCAM-1, AOPP, HbA1c and FBG in Metformin Treatment of Diabetic Nephropathy

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2018, 25(1): 50-53 https://doi.org/10.11748/bjmy.issn.1006-1703.2018.01.013

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

Funding

RIGHTS & PERMISSIONS

PDF(2918 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Revised	Published
2017-09-07	2017-09-26	2018-01-25
Issue Date
2019-01-13

Please choose a citation manager

Content to export

HeighLight

Abstract

Key words

Cite this article

{{custom_sec.title}}

{{custom_sec.title}}

References

References

{{custom_fnGroup.title_en}}

Footnotes

{{custom_ack.title_en}}

Funding

RIGHTS & PERMISSIONS